表紙
市場調査レポート

ボツリヌス中毒症 - パイプライン製品の分析

Botulism - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 277749
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
ボツリヌス中毒症 - パイプライン製品の分析 Botulism - Pipeline Review, H1 2016
出版日: 2016年02月24日 ページ情報: 英文 49 Pages
概要

ボツリヌス中毒症は、稀ですが、重篤な疾患です。ボツリヌス菌と呼ばれる細菌が作る毒素(毒)が原因です。ボツリヌス菌は、土壌に自然に存在します。食物媒介のボツリヌス中毒症は、ボツリヌス毒素で汚染された食品を食べることでもたらされます。複視や目のかすみ、眼瞼下垂、ろれつが回らない、嚥下困難、口渇、筋力低下などの症状が見られます。治療は、抗毒素、集中治療、感染創の手術などが行われます。

当レポートでは、ボツリヌス中毒症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

ボツリヌス中毒症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • XOMA Corporation
  • Planet Biotechnology Inc.
  • AlphaVax, Inc.
  • Microbiotix, Inc.
  • Hawaii Biotech, Inc.
  • Molecular Targeting Technologies, Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • XOMA-3-AB
  • Botulinum Toxin Vaccine
  • Botulinum Toxin Vaccine
  • DNA Vaccine for Botulism
  • Recombinant Peptides to Inhibit Botulinum Toxin for Botulism
  • Small Molecules for Botulism
  • Small Molecules Targeting BoNT/A LC for Botulism
  • XOMA-3-BB
  • XOMA-3-EB
  • Polyvalent BoNT Vaccine
  • Botulism Vaccine

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7627IDB

Summary

Global Markets Direct's, 'Botulism - Pipeline Review, H1 2016', provides an overview of the Botulism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Botulism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Botulism and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Botulism
  • The report reviews pipeline therapeutics for Botulism by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Botulism therapeutics and enlists all their major and minor projects
  • The report assesses Botulism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Botulism

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Botulism
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Botulism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Botulism Overview
  • Therapeutics Development
    • Pipeline Products for Botulism - Overview
    • Pipeline Products for Botulism - Comparative Analysis
  • Botulism - Therapeutics under Development by Companies
  • Botulism - Therapeutics under Investigation by Universities/Institutes
  • Botulism - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Botulism - Products under Development by Companies
  • Botulism - Products under Investigation by Universities/Institutes
  • Botulism - Companies Involved in Therapeutics Development
    • Hawaii Biotech, Inc.
    • Medytox Solutions, Inc.
    • Microbiotix, Inc.
    • Molecular Targeting Technologies, Inc.
    • XOMA Corporation
  • Botulism - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BoNT/A HcR4 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • botulinum vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • botulism [serotypes A, B, C, D, E] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • botulism [serotypes A, B] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Botulinum Toxin for Botulism - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OSX-400 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OSX-400 Backups - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Polyclonal Antibody for Botulism - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Peptides to Inhibit Botulinum Toxin for Botulism - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Botulism - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit BoNT/A LC for Botulism - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Botulinum Neurotoxin Type A for Botulism - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XOMA-3AB - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Botulism - Recent Pipeline Updates
  • Botulism - Dormant Projects
  • Botulism - Discontinued Products
  • Botulism - Product Development Milestones
    • Featured News & Press Releases
      • May 03, 2011: XOMA 3AB, New Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase I Clinical Testing
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Botulism, H1 2016
  • Number of Products under Development for Botulism - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Botulism - Pipeline by Hawaii Biotech, Inc., H1 2016
  • Botulism - Pipeline by Medytox Solutions, Inc., H1 2016
  • Botulism - Pipeline by Microbiotix, Inc., H1 2016
  • Botulism - Pipeline by Molecular Targeting Technologies, Inc., H1 2016
  • Botulism - Pipeline by XOMA Corporation, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Botulism Therapeutics - Recent Pipeline Updates, H1 2016
  • Botulism - Dormant Projects, H1 2016
  • Botulism - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Botulism, H1 2016
  • Number of Products under Development for Botulism - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top